Development Safety Update Report (DSUR)

1. lut 28, 2025

What Does 'Development Safety Update Report (DSUR)’ Mean?

A Development Safety Update Report (DSUR) is a comprehensive annual review of safety information for a drug under development. It provides a concise overview and analysis of the safety data collected during the reporting period, typically covering one year. The DSUR is designed to identify any changes to the known safety profile of the investigational drug.

DSURs are required by regulatory authorities to ensure ongoing safety monitoring throughout the clinical development process. These reports include information on serious adverse events, study discontinuations due to adverse events, and any new safety findings from clinical trials or other sources. DSURs play a crucial role in assessing the overall risk-benefit profile of an investigational drug.

Why Is the 'Development Safety Update Report (DSUR)’ Important in Clinical Research?

The DSUR is crucial in clinical research as it provides a standardized approach to ongoing safety monitoring of investigational drugs. It allows regulatory authorities, sponsors, and investigators to regularly review and assess the evolving safety profile of a drug throughout its development process, ensuring that potential risks are identified and addressed promptly.

Furthermore, the DSUR plays a vital role in supporting informed decision-making regarding the continuation of clinical trials and the overall development program. By consolidating safety data from multiple sources, it facilitates a comprehensive evaluation of the risk-benefit balance, which is essential for protecting the safety of clinical trial participants and guiding future research directions.

Good Practices and Procedures

1. Establish a cross-functional DSUR team, including representatives from clinical, regulatory, pharmacovigilance, and medical writing departments, to ensure comprehensive data collection and analysis.
2. Implement a rolling review process throughout the year, regularly updating safety information to streamline the annual DSUR compilation and reduce last-minute data rushes.
3. Develop a standardized template for investigator safety narratives to ensure consistency and completeness of reported adverse events across all clinical trial sites.
4. Conduct periodic reconciliation of safety databases with clinical trial databases to identify and resolve any discrepancies in adverse event reporting prior to DSUR submission.
5. Establish a formal review and sign-off process involving key stakeholders, including the Chief Medical Officer, to ensure accuracy and alignment with the overall benefit-risk assessment of the investigational product.

Related Terms

• Training Compliance
• Primary Endpoint
• Regulatory Intelligence